AstraZeneca: CHMP Recommends Lynparza And Imfinzi Combination For EU Approval In Endometrial Cancer

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Monday that Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union or EU as treatment for certain patients with primary advanced or recurrent endometrial cancer. https://www.nasdaq.com/articles/astrazeneca-chmp-recommends-lynparza-and-imfinzi-combination-eu-approval-endometrial